To receive your instant CE certificate, you must first "Sign In" or "Sign Up" in the top right corner.
FORMAT: Online Enduring CE Webcast
RELEASE DATE: December 17, 2020
EXPIRATION DATE: November 30, 2023
MAXIMUM CREDITS: 1.0 COPE CE Credit
CLICK HERE TO PROCEED TO PROGRAM
Learning Method and Medium
This educational activity consists of a webcast and ten (10) study questions. The participant should, in order, read the learning objectives, complete the pretest, view the webcast, answer all questions in the post test, and complete the evaluation. To receive credit for this activity, please complete the post test and evaluation. This educational activity should take a maximum of 1.0 hour to complete.
Activity Description and Purpose
Optic neuritis presents as acute, sometimes painful, vision loss, and can be a presenting sign of a wide variety of unrelated diseases. Although optic neuritis is often attributed to multiple sclerosis and treated as such, another important and underrecognized cause is neuromyelitis spectrum disorder (NMOSD). NMOSD has a more aggressive course, and often causes irreversible blindness if not recognized and treated appropriately within days of symptom onset. In this interprofessional webcast, experts in optometric and neurologic assessment and treatment of NMOSD discuss best practices in diagnosis and referral of patients with possible NMOSD as well as clinical data supporting 3 newly approved long-term suppressive treatments specifically targeting immunologic pathways altered by NMOSD autoantibodies. The desired results of this activity are to increase awareness of NMOSD among optometrists and support timely identification and referral of patients with suspected NMOSD.
Instructions for Obtaining Credit
To obtain CE credit for this activity, view the webcast, consult referenced sources as necessary, and complete the posttest and evaluation online. Upon passing with a score of 70% or higher, a certificate will be made available immediately.
This continuing education activity is provided by MedEdicus LLC.
This continuing education activity is supported through an unrestricted educational grant from Genentech, Inc.